Lila Adnane

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Tyrosine Kinase, Pathology, Pharmacotherapy +18

Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

Lila Adnane, Pamela A. Trail, I Taylor et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 2006 · 463 citations

Medicine, Receptor Tyrosine Kinase, Pharmacology +8

Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9

Heike M. Petrul, Christoph A. Schatz, Charlotte Kopitz et al. · Molecular Cancer Therapeutics · 2011 · 65 citations · Full text